Drugs & Targets CD&R, Merck GHI, and McKesson Ventures invest oncology data and informatics company M2Gen March 19, 2021Vol.47 No.11
Drugs & Targets FDA approves Fotivda for relapsed or refractory advanced renal cell carcinoma March 12, 2021Vol.47 No.10
Drugs & Targets FDA grants accelerated approval to Yescarta for relapsed or refractory follicular lymphoma March 12, 2021Vol.47 No.10
Drugs & Targets Health Canada approves Keytruda as first-line treatment for adults with MSI-H or dMMR colorectal cancer March 12, 2021Vol.47 No.10
Drugs & Targets Surface Oncology, Merck to collaborate on immuno-oncology study evaluating SRF388, targeting IL-27 + Keytruda (pembrolizumab) in solid tumors March 12, 2021Vol.47 No.10
Drugs & Targets Syapse expands strategic collaboration with Pfizer, focusing on RWE March 12, 2021Vol.47 No.10
Drugs & Targets FDA authorizes first robotically-assisted surgical device for performing transvaginal hysterectomy March 05, 2021Vol.47 No.09
Drugs & Targets FDA grants accelerated approval to Pepaxto for relapsed or refractory multiple myeloma March 05, 2021Vol.47 No.09
Drugs & Targets CHMP recommends approval of Sarclisa + carfilzomib, dexamethasone for relapsed multiple myeloma March 05, 2021Vol.47 No.09
